Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potassium bicarbonate/potassium citrate - Advicenne

Next Previous
Search
Drug Profile

Potassium bicarbonate/potassium citrate - Advicenne

Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate; Potassium citrate/potassium bicarbonate; Potassium hydrogen carbonate/potassium citrate monohydrated; Potassium-bicarbonate/potassium-citrate-Advicenne; Sibnayal

Latest Information Update: 13 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advicenne
  • Class Alkalinising agents; Citrates; Electrolytes; Potassium compounds; Small molecules; Urologics
  • Mechanism of Action Electrolyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders; Cystinuria
  • New Molecular Entity No
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • Marketed Kidney disorders
  • Phase II/III Cystinuria

Most Recent Events

  • 13 Jan 2025 No development reported - Phase-II/III for Cystinuria (In adolescents, In children, In the elderly, In infants, Treatment-experienced, In adults) in Belgium (PO)
  • 12 Mar 2024 Advicenne Pharma withdraws a phase II/III trial in Cystinuria (In infants, In children, In adolescents, In adults, In the elderly) prior to enrollment in Belgium and France due to unspecified business decision (NCT04137978) (EudraCT2017-002068-42)
  • 08 Mar 2024 Advicenne Pharma withdraws an extension to phase IIIb ARENA 2 trial for Kidney disorders (distal renal tubular acidosis) (In infants, In children, In adolescents, In adults) in USA (PO) due to completion of long term safety study in the EU (NCT03831152)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top